{
    "hands_on_practices": [
        {
            "introduction": "A key skill in preventive medicine is understanding that a diagnostic test's performance in the real world depends heavily on the prevalence of the disease. This practice  challenges you to go beyond sensitivity and specificity to calculate a test's Positive and Negative Predictive Values ($PPV$ and $NPV$). By working through the case of Prostate-Specific Antigen ($PSA$) screening, you will see why these metrics are essential for shared decision-making and for communicating the true likelihood of disease and the risk of false positives to patients.",
            "id": "4547975",
            "problem": "A primary care clinic is counseling men aged $55$–$69$ years about screening with Prostate-Specific Antigen (PSA). For this age group, suppose the PSA test has sensitivity $0.90$, specificity $0.95$, and the point prevalence of clinically significant prostate cancer is $0.02$ in the screened population. Using only fundamental definitions of sensitivity, specificity, and prevalence together with basic probability, derive expressions for the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), then compute their values for these parameters. Finally, briefly discuss how the resulting $PPV$ and $NPV$ should inform shared decision-making about PSA screening, focusing on benefits and harms in a low-prevalence setting.\n\nReport the numerical results in the order $PPV$ followed by $NPV$. Express both as decimals between $0$ and $1$ and round your answers to four significant figures. Do not use the percentage sign in your final reported values.",
            "solution": "The problem is valid as it is scientifically grounded in epidemiology and probability theory, well-posed with all necessary data provided, and objective in its formulation.\n\nLet us define the events:\n- $D$: The event that a man in the specified age group has clinically significant prostate cancer.\n- $D^c$: The event that a man does not have the disease.\n- $T$: The event that the Prostate-Specific Antigen (PSA) test is positive.\n- $T^c$: The event that the PSA test is negative.\n\nThe givens in the problem statement can be translated into probabilistic terms:\n- Prevalence of the disease, $P(D) = 0.02$.\n- The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.02 = 0.98$.\n- Sensitivity of the test, which is the probability of a positive test result given that the person has the disease: $P(T|D) = 0.90$.\n- Specificity of the test, which is the probability of a negative test result given that the person does not have the disease: $P(T^c|D^c) = 0.95$.\n\nFrom these definitions, we can also determine the probabilities of incorrect test results:\n- The false positive rate, which is the probability of a positive test given no disease: $P(T|D^c) = 1 - P(T^c|D^c) = 1 - 0.95 = 0.05$.\n- The false negative rate, which is the probability of a negative test given the presence of disease: $P(T^c|D) = 1 - P(T|D) = 1 - 0.90 = 0.10$.\n\nOur objective is to derive expressions for the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV), and then compute their values.\n\n**Derivation and Calculation of Positive Predictive Value (PPV)**\nThe PPV is the probability that a person has the disease given a positive test result, which is denoted by the conditional probability $P(D|T)$. We use Bayes' theorem to derive the expression for PPV:\n$$ \\text{PPV} = P(D|T) = \\frac{P(T|D) P(D)}{P(T)} $$\nThe denominator, $P(T)$, is the total probability of a positive test result. This can be calculated using the law of total probability, which considers both true positives and false positives:\n$$ P(T) = P(T|D) P(D) + P(T|D^c) P(D^c) $$\nSubstituting this into the expression for PPV gives the general formula:\n$$ \\text{PPV} = \\frac{P(T|D) P(D)}{P(T|D) P(D) + P(T|D^c) P(D^c)} $$\nIn terms of the standard epidemiological definitions, this is:\n$$ \\text{PPV} = \\frac{(\\text{Sensitivity}) \\times (\\text{Prevalence})}{(\\text{Sensitivity}) \\times (\\text{Prevalence}) + (1-\\text{Specificity}) \\times (1-\\text{Prevalence})} $$\nNow, we substitute the given numerical values:\n$$ \\text{PPV} = \\frac{(0.90) \\times (0.02)}{(0.90) \\times (0.02) + (1-0.95) \\times (1-0.02)} $$\n$$ \\text{PPV} = \\frac{0.018}{0.018 + (0.05) \\times (0.98)} $$\n$$ \\text{PPV} = \\frac{0.018}{0.018 + 0.049} = \\frac{0.018}{0.067} $$\n$$ \\text{PPV} \\approx 0.2686567... $$\nRounding to four significant figures, we get $\\text{PPV} \\approx 0.2687$.\n\n**Derivation and Calculation of Negative Predictive Value (NPV)**\nThe NPV is the probability that a person does not have the disease given a negative test result, denoted by $P(D^c|T^c)$. We again use Bayes' theorem:\n$$ \\text{NPV} = P(D^c|T^c) = \\frac{P(T^c|D^c) P(D^c)}{P(T^c)} $$\nThe denominator, $P(T^c)$, is the total probability of a negative test result, which includes both true negatives and false negatives. Using the law of total probability:\n$$ P(T^c) = P(T^c|D^c) P(D^c) + P(T^c|D) P(D) $$\nSubstituting this into the expression for NPV gives the general formula:\n$$ \\text{NPV} = \\frac{P(T^c|D^c) P(D^c)}{P(T^c|D^c) P(D^c) + P(T^c|D) P(D)} $$\nIn terms of the standard epidemiological definitions, this is:\n$$ \\text{NPV} = \\frac{(\\text{Specificity}) \\times (1-\\text{Prevalence})}{(\\text{Specificity}) \\times (1-\\text{Prevalence}) + (1-\\text{Sensitivity}) \\times (\\text{Prevalence})} $$\nNow, we substitute the given numerical values:\n$$ \\text{NPV} = \\frac{(0.95) \\times (1-0.02)}{(0.95) \\times (1-0.02) + (1-0.90) \\times (0.02)} $$\n$$ \\text{NPV} = \\frac{(0.95) \\times (0.98)}{(0.95) \\times (0.98) + (0.10) \\times (0.02)} $$\n$$ \\text{NPV} = \\frac{0.931}{0.931 + 0.002} = \\frac{0.931}{0.933} $$\n$$ \\text{NPV} \\approx 0.9978563... $$\nRounding to four significant figures, we get $\\text{NPV} \\approx 0.9979$.\n\n**Discussion on Shared Decision-Making**\nThe calculated Positive Predictive Value (PPV) is $0.2687$, while the Negative Predictive Value (NPV) is $0.9979$. These values are critical for informing shared decision-making between a clinician and a patient regarding PSA screening.\n\nThe high NPV ($99.79\\%$) is a primary benefit of the test. It means that a negative result provides a very high degree of confidence that the patient does not have clinically significant prostate cancer. This can provide significant reassurance.\n\nConversely, the low PPV ($26.87\\%$) is the principal source of potential harm. It demonstrates that even with a positive test, there is less than a $27\\%$ chance that the patient actually has the disease. The majority of positive tests (approximately $73\\%$) are false positives. A positive result initiates a cascade of follow-up actions, including patient anxiety and invasive diagnostic procedures like a prostate biopsy. Biopsies carry risks such as pain, bleeding, and infection. Furthermore, the issue of overdiagnosis is significant; PSA testing can detect indolent, slow-growing cancers that would never have caused symptoms or death. Treating these overdiagnosed cancers (overtreatment) exposes patients to the serious side effects of therapy (e.g., erectile dysfunction, urinary incontinence) without any clinical benefit.\n\nThe stark contrast between the test's high sensitivity ($90\\%$) and specificity ($95\\%$) and its low PPV highlights a fundamental principle of diagnostic testing: predictive values are heavily dependent on the prevalence of the disease in the population being tested. In this low-prevalence setting ($2\\%$), even a test with good intrinsic characteristics will yield a large proportion of false positives.\n\nIn a shared decision-making context, the clinician must articulate this trade-off. The discussion should focus on whether the patient's desire for the reassurance of a negative result outweighs their tolerance for the anxiety, potential complications from follow-up procedures, and risks of overdiagnosis and overtreatment that are associated with a positive result. The decision to screen is therefore a preference-sensitive one, contingent on individual patient values.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 0.2687 & 0.9979 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "Modern preventive care often relies on sophisticated tools that integrate multiple risk factors to predict future health events. This exercise  provides a look under the hood of risk calculators like the Fracture Risk Assessment Tool (FRAX) by having you build a simplified risk model. You will learn how baseline hazard rates and relative risk multipliers for factors like medical history and bone density combine to produce a personalized $10$-year fracture probability, a critical input for treatment decisions.",
            "id": "4547957",
            "problem": "A $67$-year-old woman presents for fracture risk assessment. The Fracture Risk Assessment Tool (FRAX) is widely used to estimate $10$-year probabilities of major osteoporotic fracture and hip fracture based on clinical risk factors and bone mineral density. For the purposes of this exercise, model the $10$-year fracture probabilities using an exponential survival framework grounded in survival analysis:\n\n- The hazard rate for the event of interest is assumed constant over time, with the survival function given by $S(t) = \\exp(-\\lambda t)$, where $\\lambda$ is the hazard rate and $t$ is time in years.\n- The $10$-year probability of event is $P = 1 - \\exp(-\\lambda \\cdot 10)$.\n- The individual hazard rate is modeled as a multiplicative function of a baseline hazard and risk factor multipliers: $\\lambda = \\lambda_{0} \\times \\prod_{i} \\text{RR}_{i}$, where $\\lambda_{0}$ is the baseline hazard rate for a referent patient (same age and sex, with no clinical risk factors and a femoral neck $T$-score of $0$), and $\\text{RR}_{i}$ are well-established relative risk multipliers for each risk factor.\n\nAssume the following baseline annual hazard rates (per year) for a $67$-year-old woman in the United States reference population:\n- Major osteoporotic fracture baseline hazard: $\\lambda_{0,\\mathrm{major}} = 0.013$.\n- Hip fracture baseline hazard: $\\lambda_{0,\\mathrm{hip}} = 0.0035$.\n\nAssume the following validated log-linear hazard multipliers for risk factors (to be applied multiplicatively), which reflect meta-analytic evidence underlying FRAX-type models:\n- Prior fragility fracture: $\\text{RR}_{\\mathrm{major}} = 1.5$, $\\text{RR}_{\\mathrm{hip}} = 1.2$.\n- Glucocorticoid use (systemic, $\\geq 3$ months): $\\text{RR}_{\\mathrm{major}} = 1.2$, $\\text{RR}_{\\mathrm{hip}} = 1.4$.\n- Secondary osteoporosis (for example, type $1$ diabetes mellitus): $\\text{RR}_{\\mathrm{major}} = 1.2$, $\\text{RR}_{\\mathrm{hip}} = 1.1$.\n- Femoral neck bone mineral density $T$-score effect (continuous), referenced to $T=0$: for major fracture, $\\text{RR}_{\\mathrm{BMD,major}}(T) = 1.3^{|T|}$; for hip fracture, $\\text{RR}_{\\mathrm{BMD,hip}}(T) = 1.6^{|T|}$.\n\nThe patient’s risk profile is:\n- Prior fragility fracture: yes.\n- Parental hip fracture: no.\n- Current smoking: no.\n- Glucocorticoid use (systemic, $\\geq 3$ months): yes.\n- Rheumatoid arthritis: no.\n- Secondary osteoporosis: yes (type $1$ diabetes mellitus).\n- Alcohol intake $\\geq 3$ units/day: no.\n- Femoral neck $T$-score: $-2.1$.\n\nUse the exponential survival framework and the provided multipliers to estimate the $10$-year probabilities for:\n- Major osteoporotic fracture.\n- Hip fracture.\n\nGuideline thresholds for initiating pharmacologic therapy are:\n- Initiate if $10$-year hip fracture probability $\\geq 0.03$ or $10$-year major osteoporotic fracture probability $\\geq 0.20$.\n\nTasks:\n- Compute the $10$-year major osteoporotic fracture probability and the $10$-year hip fracture probability as decimals. Round each probability to four significant figures.\n- Decide whether to initiate pharmacotherapy under the guideline thresholds. For the decision, report the numeric code $1$ for “initiate pharmacotherapy” and $0$ for “do not initiate pharmacotherapy.”\n- Your final boxed answer should be the decision code only. No units are required for the probabilities, and do not use the percentage sign.",
            "solution": "The problem requires the calculation of $10$-year fracture probabilities for a specific patient using a provided exponential survival model and a set of risk multipliers. The decision to initiate pharmacotherapy is then based on comparing these probabilities to given clinical thresholds. The problem is scientifically grounded, well-posed, and all necessary data are provided.\n\nThe core model is based on a constant hazard rate, $\\lambda$. The survival function over a time period $t$ is $S(t) = \\exp(-\\lambda t)$. The probability of an event occurring within a time period $T_p$ is $P(T_p) = 1 - S(T_p) = 1 - \\exp(-\\lambda T_p)$. For this problem, the time period is $T_p = 10$ years, so the probability is $P = 1 - \\exp(-10\\lambda)$.\n\nThe patient-specific hazard rate, $\\lambda$, is determined by multiplying a baseline hazard rate, $\\lambda_0$, by the relative risks ($\\text{RR}_i$) associated with the patient's specific risk factors. The general formula is $\\lambda = \\lambda_0 \\times \\prod_{i} \\text{RR}_i$.\n\nThe patient is a $67$-year-old woman with the following risk factors:\n1.  Prior fragility fracture: Yes.\n2.  Glucocorticoid use: Yes.\n3.  Secondary osteoporosis: Yes.\n4.  Femoral neck $T$-score: $-2.1$.\n\nThe risk factors not present (parental hip fracture, smoking, high alcohol intake, rheumatoid arthritis) have a relative risk multiplier of $1$ and do not need to be included in the product.\n\nFirst, we will calculate the $10$-year probability of major osteoporotic fracture, $P_{\\mathrm{major}}$.\nThe baseline annual hazard rate for major fracture is $\\lambda_{0,\\mathrm{major}} = 0.013$.\nThe relevant relative risk multipliers for major fracture are:\n- Prior fragility fracture: $\\text{RR}_{\\mathrm{prior-fx,major}} = 1.5$.\n- Glucocorticoid use: $\\text{RR}_{\\mathrm{gc,major}} = 1.2$.\n- Secondary osteoporosis: $\\text{RR}_{\\mathrm{so,major}} = 1.2$.\n- Femoral neck $T$-score of $T = -2.1$: The multiplier is given by $\\text{RR}_{\\mathrm{BMD,major}}(T) = 1.3^{|T|}$. For this patient, $\\text{RR}_{\\mathrm{BMD,major}} = 1.3^{|-2.1|} = 1.3^{2.1}$.\n\nThe patient's total annual hazard rate for major fracture, $\\lambda_{\\mathrm{major}}$, is the product of the baseline hazard and the multipliers for the present risk factors:\n$$ \\lambda_{\\mathrm{major}} = \\lambda_{0,\\mathrm{major}} \\times \\text{RR}_{\\mathrm{prior-fx,major}} \\times \\text{RR}_{\\mathrm{gc,major}} \\times \\text{RR}_{\\mathrm{so,major}} \\times \\text{RR}_{\\mathrm{BMD,major}} $$\n$$ \\lambda_{\\mathrm{major}} = 0.013 \\times 1.5 \\times 1.2 \\times 1.2 \\times 1.3^{2.1} $$\nLet's first calculate the product of the discrete risk factors: $1.5 \\times 1.2 \\times 1.2 = 2.16$.\n$$ \\lambda_{\\mathrm{major}} = 0.013 \\times 2.16 \\times 1.3^{2.1} \\approx 0.013 \\times 2.16 \\times 1.73483 \\approx 0.048714 $$\nNow, we calculate the $10$-year probability of major osteoporotic fracture, $P_{\\mathrm{major}}$:\n$$ P_{\\mathrm{major}} = 1 - \\exp(-10 \\cdot \\lambda_{\\mathrm{major}}) \\approx 1 - \\exp(-10 \\cdot 0.048714) = 1 - \\exp(-0.48714) $$\n$$ P_{\\mathrm{major}} \\approx 1 - 0.61439 = 0.38561 $$\nRounding to four significant figures, the probability is $P_{\\mathrm{major}} \\approx 0.3856$.\n\nNext, we will calculate the $10$-year probability of hip fracture, $P_{\\mathrm{hip}}$.\nThe baseline annual hazard rate for hip fracture is $\\lambda_{0,\\mathrm{hip}} = 0.0035$.\nThe relevant relative risk multipliers for hip fracture are:\n- Prior fragility fracture: $\\text{RR}_{\\mathrm{prior-fx,hip}} = 1.2$.\n- Glucocorticoid use: $\\text{RR}_{\\mathrm{gc,hip}} = 1.4$.\n- Secondary osteoporosis: $\\text{RR}_{\\mathrm{so,hip}} = 1.1$.\n- Femoral neck $T$-score of $T = -2.1$: The multiplier is given by $\\text{RR}_{\\mathrm{BMD,hip}}(T) = 1.6^{|T|}$. For this patient, $\\text{RR}_{\\mathrm{BMD,hip}} = 1.6^{|-2.1|} = 1.6^{2.1}$.\n\nThe patient's total annual hazard rate for hip fracture, $\\lambda_{\\mathrm{hip}}$, is:\n$$ \\lambda_{\\mathrm{hip}} = \\lambda_{0,\\mathrm{hip}} \\times \\text{RR}_{\\mathrm{prior-fx,hip}} \\times \\text{RR}_{\\mathrm{gc,hip}} \\times \\text{RR}_{\\mathrm{so,hip}} \\times \\text{RR}_{\\mathrm{BMD,hip}} $$\n$$ \\lambda_{\\mathrm{hip}} = 0.0035 \\times 1.2 \\times 1.4 \\times 1.1 \\times 1.6^{2.1} $$\nThe product of the discrete risk factors is: $1.2 \\times 1.4 \\times 1.1 = 1.848$.\n$$ \\lambda_{\\mathrm{hip}} = 0.0035 \\times 1.848 \\times 1.6^{2.1} \\approx 0.0035 \\times 1.848 \\times 2.68305 \\approx 0.017356 $$\nNow, we calculate the $10$-year probability of hip fracture, $P_{\\mathrm{hip}}$:\n$$ P_{\\mathrm{hip}} = 1 - \\exp(-10 \\cdot \\lambda_{\\mathrm{hip}}) \\approx 1 - \\exp(-10 \\cdot 0.017356) = 1 - \\exp(-0.17356) $$\n$$ P_{\\mathrm{hip}} \\approx 1 - 0.84067 = 0.15933 $$\nRounding to four significant figures, the probability is $P_{\\mathrm{hip}} \\approx 0.1593$.\n\nFinally, we apply the clinical guidelines to decide on pharmacotherapy. Therapy should be initiated if $P_{\\mathrm{major}} \\geq 0.20$ or $P_{\\mathrm{hip}} \\geq 0.03$.\n- Comparing the major osteoporotic fracture probability: $0.3856 \\geq 0.20$. This condition is met.\n- Comparing the hip fracture probability: $0.1593 \\geq 0.03$. This condition is also met.\n\nSince at least one of the conditions is met (in this case, both are), the decision is to initiate pharmacotherapy. The numeric code for this decision is $1$.",
            "answer": "$$ \\boxed{1} $$"
        },
        {
            "introduction": "Implementing a screening program requires balancing potential benefits against the costs and resources needed. After determining a patient's eligibility for a screening test, a crucial public health question is: how efficient is the program at preventing adverse outcomes? This problem  asks you to apply clinical guidelines for lung cancer screening and then calculate the Number Needed to Screen ($NNS$), a powerful metric that quantifies the population-level effort required to prevent a single death from the disease.",
            "id": "4548001",
            "problem": "A clinician must decide whether a $54$-year-old woman should receive Low-Dose Computed Tomography (LDCT) lung cancer screening and estimate the expected number needed to screen to prevent one lung cancer death in this context. The patient has a $25$ pack-year smoking history and quit smoking $10$ years ago. Use the United States Preventive Services Task Force (USPSTF) guideline criteria for LDCT lung cancer screening eligibility: age $50$ to $80$ years, at least $20$ pack-years of smoking, and current smoking or having quit within the past $15$ years.\n\nFor estimation, adopt the following well-tested facts to ground your calculation:\n\n- In a high-risk eligible population similar to the National Lung Screening Trial (NLST), the $6$-year cumulative lung cancer mortality risk without LDCT screening is $p_{0} = 0.015$.\n- LDCT screening, when implemented with adherence similar to NLST protocols, yields a cause-specific lung cancer mortality relative risk reduction of $R = 0.20$ over approximately $6$ years.\n\nStarting from the core definitions of eligibility and risk reduction, determine whether this patient is eligible for LDCT screening under USPSTF criteria. Then, derive an expression for the absolute risk reduction and compute the expected number needed to screen (NNS) over the $6$-year horizon to prevent one lung cancer death in this population. Round your final NNS to three significant figures. Express your final answer as a pure number with no units.",
            "solution": "The problem will first be validated to ensure it is scientifically sound, well-posed, and objective.\n\nStep 1: Extract Givens\nPatient data:\n- Age: $54$ years\n- Smoking history: $25$ pack-years\n- Time since quitting: $10$ years\nUSPSTF guideline criteria for LDCT lung cancer screening eligibility:\n- Age: $50$ to $80$ years\n- Smoking history: at least $20$ pack-years\n- Smoking status: current smoker or quit within the past $15$ years\nEpidemiological data from a high-risk population (e.g., NLST):\n- $6$-year cumulative lung cancer mortality risk without screening (baseline risk): $p_{0} = 0.015$\n- Cause-specific lung cancer mortality relative risk reduction from LDCT: $R = 0.20$\n- Time horizon: approximately $6$ years\nRequired outputs:\n1. Determination of the patient's eligibility for LDCT screening.\n2. Derivation of an expression for the absolute risk reduction.\n3. Calculation of the expected number needed to screen (NNS), rounded to three significant figures.\n\nStep 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria.\n- **Scientifically Grounded:** The problem uses standard, well-established concepts and terminology from preventive medicine and epidemiology, such as pack-years, risk, relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to screen (NNS). The context is the United States Preventive Services Task Force (USPSTF) guidelines for lung cancer screening, which are evidence-based and widely used in clinical practice. The risk data provided ($p_0 = 0.015$, $R=0.20$) are consistent with the landmark National Lung Screening Trial (NLST), which forms the primary evidence base for these guidelines. The problem is free of pseudoscience and is scientifically sound.\n- **Well-Posed:** The problem provides all necessary information to determine eligibility and to calculate the requested epidemiological measures. The question is unambiguous and leads to a unique, stable solution.\n- **Objective:** The language is precise, quantitative, and free of subjective or opinion-based statements.\n\nThe problem does not exhibit any of the flaws listed in the validation checklist. It is scientifically sound, complete, realistic, and well-posed.\n\nStep 3: Verdict and Action\nThe problem is deemed valid. A solution will be provided.\n\nThe solution proceeds in three parts as requested: determining eligibility, deriving the expression for absolute risk reduction, and computing the number needed to screen.\n\nPart 1: Patient Eligibility\nTo determine if the $54$-year-old woman is eligible for LDCT screening, we must verify that she meets all three of the USPSTF criteria provided.\n1.  **Age Criterion:** The required age range is $50$ to $80$ years. The patient's age is $54$. Since $50 \\le 54 \\le 80$, this criterion is met.\n2.  **Smoking History Criterion:** The requirement is at least a $20$ pack-year smoking history. The patient has a $25$ pack-year history. Since $25 \\ge 20$, this criterion is met.\n3.  **Smoking Status Criterion:** The requirement is to be a current smoker or to have quit within the past $15$ years. The patient quit $10$ years ago. Since $10 \\le 15$, this criterion is met.\n\nSince the patient satisfies all three criteria, she is eligible for annual LDCT lung cancer screening under the specified USPSTF guidelines.\n\nPart 2: Derivation and Calculation of Absolute Risk Reduction (ARR)\nThe absolute risk reduction is the difference between the event rate in the control group and the event rate in the treatment (or screening) group. Let $p_0$ be the risk of lung cancer death in the unscreened (control) group and $p_1$ be the risk of lung cancer death in the screened (intervention) group.\nThe Absolute Risk Reduction (ARR) is defined as:\n$$ARR = p_0 - p_1$$\nThe problem provides the relative risk reduction, $R$, which is defined as the proportional reduction in risk in the screened group compared to the unscreened group:\n$$R = \\frac{p_0 - p_1}{p_0}$$\nFrom this definition, we can express $p_1$ in terms of $p_0$ and $R$:\n$$R \\cdot p_0 = p_0 - p_1$$\n$$p_1 = p_0 - R \\cdot p_0 = p_0 (1 - R)$$\nNow, we substitute this expression for $p_1$ back into the definition of ARR:\n$$ARR = p_0 - p_0(1 - R) = p_0 - p_0 + p_0 \\cdot R$$\nThis simplifies to the derived expression for ARR in terms of the given quantities:\n$$ARR = p_0 \\cdot R$$\nUsing the provided values, $p_0 = 0.015$ and $R = 0.20$:\n$$ARR = 0.015 \\times 0.20 = 0.003$$\n\nPart 3: Calculation of the Number Needed to Screen (NNS)\nThe Number Needed to Screen (NNS) is the expected number of individuals who must undergo the screening intervention over the specified time period to prevent one adverse outcome (in this case, one lung cancer death). It is the reciprocal of the absolute risk reduction.\n$$NNS = \\frac{1}{ARR}$$\nUsing the expression for ARR derived in Part 2, we have:\n$$NNS = \\frac{1}{p_0 \\cdot R}$$\nSubstituting the numerical values:\n$$NNS = \\frac{1}{0.015 \\times 0.20} = \\frac{1}{0.003}$$\n$$NNS = \\frac{1000}{3} = 333.333...$$\nThe problem requires the answer to be rounded to three significant figures.\nThe number $333.333...$ rounded to three significant figures is $333$.\n\nTherefore, the patient is eligible for screening, and the expected number needed to screen to prevent one lung cancer death in this population over a $6$-year horizon is $333$.",
            "answer": "$$\n\\boxed{333}\n$$"
        }
    ]
}